Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-(11C) methionine is a synthetic radiolabeled amino acid, specifically the essential amino acid methionine tagged with the radioactive isotope carbon‑11. It acts as a methyl donor and is incorporated into macromolecules during protein synthesis. Its primary use is as a positron emission tomography (PET) imaging agent for detecting tumors, especially those with high rates of protein synthesis such as brain, head and neck, lung, and breast cancers, as well as lymphomas. The uptake of L-(11C) methionine in tissues is mediated by large neutral amino acid transporters (notably LAT1), which are often overexpressed in tumor cells. This property allows for sensitive detection and delineation of active tumor tissue compared to normal tissue or post-treatment changes[1][2][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-(11C) methionine.